USFDA Product Approval
Aurobindo Pharma Receives Final US FDA Approval for Tofacitinib Tablets 5 mg and 10 mg; Launch Planned Immediately
NSE
auropharma
BSE
524804
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets 5 mg and 10 mg. The product is therapeutically equivalent to Pfizer’s reference listed drug (RLD) Xeljanz. The company plans an immediate commercial launch in the United States, targeting a market estimated at approximately US$494 million.
PRICE-SENSITIVE TRIGGER
Event: Receipt of final USFDA approval for Tofacitinib Tablets 5 mg and 10 mg.
Type: USFDA Product Approval
Impact: Positive
Immediate Effect: The approval expands Aurobindo’s U.S. generics portfolio and enables immediate entry into a sizeable therapeutic market, supporting future revenue opportunities from the company’s regulated markets business.
Key Metrics:
- Estimated U.S. Market Size (IQVIA MAT, April 2026): US$494 million
- Total ANDA Approvals from USFDA: 586
- Final ANDA Approvals: 561
- Tentative ANDA Approvals: 25
Highlight:
- Aurobindo has received final USFDA approval for Tofacitinib Tablets and plans immediate commercialization in a U.S. market estimated at approximately US$494 million.
What Happened ?
Aurobindo Pharma announced that it has secured final approval from the USFDA for Tofacitinib Tablets in 5 mg and 10 mg strengths.
The approved product is bioequivalent and therapeutically equivalent to Xeljanz Tablets, the reference listed drug marketed by Pfizer. Manufacturing will be undertaken at APL Healthcare Unit IV, a wholly owned subsidiary of Aurobindo Pharma.
The company stated that commercial launch activities will commence immediately following the approval.
Key Details
USFDA Approval and Product Commercialization:
- Final USFDA approval received for Tofacitinib Tablets 5 mg and 10 mg.
- Product is therapeutically equivalent to Pfizer’s Xeljanz Tablets.
- Approval covers both 5 mg and 10 mg strengths.
- Manufacturing will be carried out at APL Healthcare Unit IV.
- APL Healthcare Unit IV is a wholly owned subsidiary of Aurobindo Pharma.
- Product launch in the U.S. market is planned immediately.
- Estimated addressable U.S. market size is approximately US$494 million.
- Tofacitinib is used in the treatment of rheumatoid arthritis.
- Product is also indicated for psoriatic arthritis.
- Product is approved for treatment of ulcerative colitis in eligible patients.
- Approval strengthens Aurobindo’s regulated markets portfolio.
- Total USFDA ANDA approvals now stand at 586.
Note:
- The approval enhances Aurobindo’s presence in the specialty and complex generics segment while expanding its U.S. portfolio in immunology and inflammatory disease therapies.
Risk Analysis
Summary:
- While regulatory approval removes a key development risk, commercial performance will depend on market penetration, competitive intensity, pricing dynamics, and generic substitution rates in the U.S. market.
Key Risks:
- Revenue realization depends on successful commercial launch.
- Generic competition may impact pricing and market share.
- Market opportunity may be fragmented among multiple manufacturers.
- Regulatory compliance requirements remain ongoing post-launch.
- Actual sales may vary from the estimated market opportunity.
- U.S. generic pricing pressure could affect profitability.
Worst Case Scenario:
- Intense generic competition and pricing erosion could limit market share gains and reduce the commercial value derived from the approval.
Risk Level: Low
Company Commentary
- The company has received final USFDA approval for Tofacitinib Tablets 5 mg and 10 mg.
- The product is bioequivalent and therapeutically equivalent to the reference listed drug Xeljanz.
- Manufacturing will be undertaken through APL Healthcare Unit IV.
- Commercial launch will be initiated immediately.
- The approval further strengthens Aurobindo’s U.S. generics portfolio.
- Total USFDA ANDA approvals have increased to 586.
Official Exchange Filing: Aurobindo Pharma Limited